BioCentury
ARTICLE | Clinical News

Gastric cancer data show Opdivo's survival benefit

January 19, 2017 9:21 PM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) said data from a Phase III study of Opdivo nivolumab to treat gastric cancer showed that the PD-1 inhibitor led to median overall survival (OS) of 5.32 months vs. 4.14 months for placebo (p<0.0001). The trial, ONO-4538-12, evaluated Opdivo in patients with unresectable advanced or recurrent gastric cancer refractory to or intolerant of standard therapy.

BMS and partner Ono Pharmaceutical Co. Ltd. (Tokyo:4528) had said in November that Opdivo met the trial's primary endpoint measuring OS, and that Opdivo was the first immuno-oncology candidate to show a survival benefit in gastric cancer (see BioCentury Extra, Nov. 10, 2016)...